Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kanazawa Ken, Hayashi Koji, Xinyi Cao, Hijikata Mai, Kuwabara Koichiro
Аннотация
OBJECTIVE: To evaluate the clinical feasibility of a low-dose tirzepatide strategy in older adults with type 2 diabetes mellitus in routine outpatient practice.
METHODS: This single-center retrospective cohort included Japanese adults who initiated tirzepatide between April 2024 and December 2025 and received a maximum observed dose of ≤5 mg/week through week 28. The primary endpoint in adults aged ≥65 years combined treatment persistence, absence of adverse event (AE)-related discontinuation, and either ≥3% weight loss or an HbA1c reduction ≥1.0 percentage point (≥11 mmol/mol). Younger adults were contextual comparators using overlap weighting.
RESULTS: Among 122 tirzepatide initiators, 107 were included in the low-dose strategy cohort, including 37 older adults. The primary endpoint was achieved by 23/37 (62.2%); 33/37 (89.2%) remained on treatment, and 2/37 (5.4%) discontinued because of AEs. Median body weight change was -3.07%, median HbA1c change was -1.0 percentage point (-11 mmol/mol), and 19/37 (51.4%) achieved HbA1c <7.0% (<53 mmol/mol). Renal, hydration, and nutritional laboratory markers remained generally stable. Overlap-weighted comparisons showed no clear age-related attenuation.
CONCLUSION: In selected older adults, low-dose tirzepatide provided modest metabolic benefit with high persistence and infrequent AE-related discontinuation.
METHODS: This single-center retrospective cohort included Japanese adults who initiated tirzepatide between April 2024 and December 2025 and received a maximum observed dose of ≤5 mg/week through week 28. The primary endpoint in adults aged ≥65 years combined treatment persistence, absence of adverse event (AE)-related discontinuation, and either ≥3% weight loss or an HbA1c reduction ≥1.0 percentage point (≥11 mmol/mol). Younger adults were contextual comparators using overlap weighting.
RESULTS: Among 122 tirzepatide initiators, 107 were included in the low-dose strategy cohort, including 37 older adults. The primary endpoint was achieved by 23/37 (62.2%); 33/37 (89.2%) remained on treatment, and 2/37 (5.4%) discontinued because of AEs. Median body weight change was -3.07%, median HbA1c change was -1.0 percentage point (-11 mmol/mol), and 19/37 (51.4%) achieved HbA1c <7.0% (<53 mmol/mol). Renal, hydration, and nutritional laboratory markers remained generally stable. Overlap-weighted comparisons showed no clear age-related attenuation.
CONCLUSION: In selected older adults, low-dose tirzepatide provided modest metabolic benefit with high persistence and infrequent AE-related discontinuation.